Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy

Item

http://www.wikidata.org/entity/Q34743875

Q34743875

about

PI3K/AKT/mTOR Pathway in Angiogenesis Antiangiogenic Steroids in Human Cancer Therapy.Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis Mechanisms underlying skin disorders induced by EGFR inhibitors Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy Identification of potent EGFR inhibitors from TCM Database@Taiwan Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.Tumour vascularization: sprouting angiogenesis and beyond Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis.Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis.Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer The RON tyrosine kinase receptor regulates vascular endothelial growth factor production in pancreatic cancer cells.Human epidermal growth factor receptor 2 expression in urothelial carcinoma of the renal pelvis: correlation with clinicopathologic parameters Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas.Jeremiah Metzger Lecture. Targeted cancer therapy HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics.Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft.Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.miR-29a suppresses growth and invasion of gastric cancer cells in vitro by targeting VEGF-A.Molecular imaging in therapeutic efficacy assessment of targeted therapy for nonsmall cell lung cancer Targeting HER2 in breast cancer: overview of long-term experience Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers Molecular targeting to treat gastric cancer.Development of an ErbB-overexpressing A-431 optical reporting tumor xenograft model to assess targeted photodynamic therapy regimens.New approaches in angiogenic targeting for colorectal cancer.The hemostatic system and angiogenesis in malignancy.Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts.Targeted inhibition of kinases in cancer therapy Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways.Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.Identification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer.Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer

P2860

Q21129332-EC0AC976-19CE-410A-AA3A-DE277F67D9AF Q24795360-31674E0F-6F0C-4D7C-A3C7-E3BFF6196E7F Q24803543-E11DBCB7-880F-4AEB-82E1-0943A14846A8 Q24805089-6A706A07-662D-4ABB-B684-9FA2E94D545D Q26745689-33C5FF29-12A6-4566-8229-E1BF8E8746FD Q28475894-C598ACB8-7890-47D7-8B6E-7BE9DFB9E012 Q28477481-4317DBD6-8C34-45AB-8E8A-E53F4504E361 Q33257718-047DA64B-BF3F-463F-8F64-465C2D8EC063 Q33441143-D53C94BE-88E5-4C8D-A7B6-B98CA8DDBDAA Q33556162-2475DB4E-5D58-474A-8D9E-267742EBE621 Q33622614-277BC5AC-11EA-46F9-A068-23060152F4E5 Q33644407-277A9317-DD3D-42FE-BB2A-D66206480F53 Q33658544-BE67972A-772F-44DD-9429-85A4D033F940 Q33710084-07770684-1DEA-41A8-9722-213CDA548DDE Q33745294-B320ADCC-0B81-4F74-ABA6-4B5050D5DA50 Q33768073-931AA634-5832-40FE-9729-81261AAA5B5E Q33802832-DAB1B744-5CEE-49B0-AC19-2BDFFD0FB780 Q33831958-FB8F86B9-52E1-4B47-BEB2-F3BA24026B6C Q33931775-C7BD8135-032D-45B1-B7FA-663C50CEA9EF Q33943812-3B7CDA55-906F-44B7-9255-F37B3D6D2FAA Q33958678-F89A7EFC-89D2-43BB-83BD-E704151E916F Q33968465-ECFB3A05-C0B7-437F-87D5-B90E782AD0B1 Q34095952-BA5C36B6-0CD4-4A1D-AE86-68DD1AF9D545 Q34128501-7192B61B-DC53-466B-8B35-E7E9CCE56B4A Q34132872-2748CEE9-C11E-44F3-A8AC-A29898481AE6 Q34179800-2D2E5A86-66BE-420F-9D7B-58F42520EA14 Q34243500-8A629374-C82E-40B5-8D7E-EAF38EFEC107 Q34272044-1A8C987F-3BEC-45E3-AA0A-0C0CDEF526DD Q34274718-F561E325-DEC0-4ECD-BD4A-62FF26191E3C Q34326593-733BE7D7-2033-42E8-A6A7-D3360D229E03 Q34349345-48E4519F-FDE5-4105-9E33-C37BAB678B6D Q34382785-B3A74E6B-BD04-4843-A7C1-EE626313F2CB Q34425462-A1C56237-6A52-4A44-9BF9-548459BD0B61 Q34482756-0784DC3A-0092-4377-9132-5B2BCBAB188D Q34683348-AFC1482C-83C3-4284-A3A1-8EBE04382211 Q34787415-2ACCF3A5-8A69-4B66-921C-D0C826B2800C Q35001415-EB545A6D-AB15-4425-9252-B8FA7F35B71F Q35014817-BB260562-29BE-4ABC-8CD6-5835094ECA72 Q35030421-1AF55FE1-BCD7-4696-B62A-90FD16B8471C Q35076220-6389F066-B5B1-4B48-9889-2BC2C2EEADB2

P2860

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy

Item

http://www.wikidata.org/entity/Q34743875

description

1997 nî lūn-bûn

@nan

1997 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年学术文章

@wuu

1997年学术文章

@zh-cn

1997年学术文章

@zh-hans

1997年学术文章

@zh-my

1997年学术文章

@zh-sg

1997年學術文章

@yue